DJ Telix Pharmaceuticals Limited (TLX-AU): Updated PCa imaging guidelines de-risk lead asset
Dow Jones received a payment from EQS/DGAP to publish this press release.
goetzpartners securities Limited
Telix Pharmaceuticals Limited (TLX-AU): Updated PCa imaging guidelines de-risk
lead asset
18-March-2019 / 20:05 GMT/BST
*Free to access research and investor meetings in a post-MiFID2 world.*
*This research report is intended for use only by persons who qualify as
professional investors or eligible counterparties (institutional investors) in
the applicable jurisdiction, and not by any private individuals or other
persons who qualify as retail clients.*
*Published to the market and investors on 18th March 2019 @ 7.54pm (GMT).*
*Telix Pharmaceuticals Limited (TLX-AU): Updated PCa imaging guidelines
de-risk lead asset*
*Recommendation: OUTPERFORM*
*Target Price: AUD$ 2.50*
*Current Price: AUD$ 0.86 (CoB on 18th March 2019) *
*KEY TAKEAWAY*
Telix Pharmaceuticals today announced the inclusion of PSMA-PET in the
European Association of Urology's ("EAU") clinical guidance for the management
of prostate cancer in patients with suspected recurrent disease, which should
provide a significant boost to Telix's illumet (68Ga PSMA-11) PSMA-PET imaging
agent. Already used as a companion diagnostic in Endocyte's ongoing pivotal
prostate cancer Phase III trial and the subject of a distribution deal with
Cardinal Health in the US, inclusion of PSMA-PET should facilitate both
regulatory approval and adoption of 68Ga PSMA-11 in Europe. Telix's own Phase
III-ready radiopharmaceutical TLX-591 shows better efficacy and tolerability
compared to Endocyte's 177Lu-PSMA-617. With renal cancer and glioma programmes
progressing, Telix looks undervalued, in our view. We reiterate both our
OUTPERFORM recommendation and AUD 2.50 target price.
*PSMA-PET superior* - The subject of many clinical studies, 68Ga PSMA-11 has
been recommended for primary staging of high-risk patients and for all
secondary staging in prostate cancer by key opinion leaders (Virgolini, 2018).
In head-to-head studies it has been found to be superior to other metabolic
PET-based diagnostics such as F-18 fluciclovine / FACBC (Axumin) or
choline in the detection and monitoring of recurrent disease (Evans, 2018).
*Inclusion in EAU guidelines opens door to regulatory approval* - EAU
guidelines form an important role in the standardisation of prostate cancer
care in Europe, and inclusion of PSMA-PET should facilitate adoption and
smooth market approval.
*US deals already in place* - Available in a convenient 'shake and shoot'
format as illumet, the Telix prostate imaging agent is already distributed by
market leader Cardinal Health for Investigational use and utilised as a
companion diagnostic in the current Endocyte pivotal Phase III trial.
*Superior prostate cancer therapy ready for Phase III *- With optimised
fractionated dosing shown to reduce previous dose-limiting blood toxicities,
unpublished cross-trial comparison data indicates that the Telix 591
177Lu-PSMA-antibody may provide a forty month mean overall survival compared
to the 13.5 months reported for Endocyte's 177Lu-PSMA-617. A Phase III trial
is due begin by YE2019E. The antibody-linked format also avoids debilitating
damage to the lacrimal and salivary glands associated with the Endocyte
product, opening the door to earlier use and combination with
androgen-depletion therapies such as Johnson and Johnson's abiraterone.
*Just part of diversified portfolio* - With ongoing late stage clinical
programmes progressing in renal cancer imaging and therapy as well as
glioblastoma, Telix's prostate cancer programme forms just part of a
diversified and significantly de-risked product pipeline.
*Undervalued* - Telix looks undervalued, in our view, just on the basis of
$2.1bn paid by Novartis for Endocyte. Our DCF analysis indicates that the
current market valuation is largely justified on the basis of the imaging
programmes alone and ascribes modest value to therapeutics; despite the
quality of data in all three programmes. Our risk adjusted analysis indicates
a fair value of AUD 2.50 per share with upside of AUD 4.50 per share should
the products achieve their full therapeutic potential.
Kind regards,
Martin Piehlmeier | Analyst
goetzpartners Healthcare Research Team | Research Team
goetzpartners securities Limited
The Stanley Building, 7 Pancras Square, London, N1C 4AG, England, UK.
T +44 (0) 203 859 7725 | martin.piehlmeier@goetzpartners.com /
healthcareresearch@goetzpartners.com
www.goetzpartnerssecurities.com [1]
goetzpartners securities LinkedIn page [2]
Registered in England No. 04684144.
Managing Directors: Dr Stephan Goetz, Martin Brunninger and Ulrich Kinzel.
*goetzpartners securities Limited - Team Members*
Equity Research Analysts - Martin Brunninger, Brigitte de Lima, Chris Redhead,
Martin Piehlmeier and Kieron Banerjee.
Sales / Marketing - Erland Sternby.
Corporate Finance - Ulrich Kinzel, Wolf Dornbusch and Youchen Xin.
Corporate Access and IR - Tanya Tracey and Bettina Ellinghorst.
Compliance - Paul W. Dunne.
Click here [3] to see our privacy policy.
GPSL has a formal client relationship with Telix Pharmaceuticals Limited.
GPSL publishes and distributes "Investment" Research and "Corporate Sponsored"
Research. Our Corporate Sponsored Research and investor meetings (e.g. NDRs, 1
to 1 meetings) are free to access and attend and is not classified as an
inducement in a post-MiFID2 world, this is because the issuer is paying GPSL.
GPSL does not offer any execution or market making services. This is a
marketing communication as defined by the Financial Conduct Authority ("FCA").
The information herein is considered to be an acceptable minor non-monetary
benefit as defined under FCA COBS 2.3A19(5).
In accordance with the General Data Protection Regulation ("GDPR [4]") - if
you would like to be removed / unsubscribed from our CRM (also please note
that you are free to contact GPSL at any time in the future to have your
e-mail subscription amended), please e-mail:
researchproduction@goetzpartners.com
About GPSL [1]: goetzpartners securities Limited is a member of the
goetzpartners group, and a leading pan European investment bank and research
company. We bring together a wide range of expertise, insights and innovations
to advance the interests of our clients around the world. The fast-changing
environment brings challenges for businesses and investors. Research
innovation, digital transformation and disruptive business ideas reshuffle the
corporate world at a relentless pace. Our sector knowledge and our global
footprint bring together corporate intelligence and a deep understanding of
the industry with a wide network of top decision makers. These collective
insights help our clients to stay at the leading edge of change.
This research report is intended for use only by persons who qualify as
professional investors or eligible counterparties (institutional investors) in
the applicable jurisdiction, and not by any private individuals or other
persons who qualify as retail clients.
This communication (including any attachments) from goetzpartners securities
Limited ("GPSL") is confidential and may contain information which is
proprietary, privileged or otherwise legally protected against unauthorised
use or disclosure. If you receive this communication in error or are not the
intended recipient of this communication, please delete and destroy all copies
in your possession, notify the sender that you have received this
communication, and note that any review or dissemination of, or the taking of
any action in reliance on this communication is expressly prohibited. GPSL
shall not be liable for the improper or incomplete transmission of the
information contained in this communication nor for any delay in its receipt
or damage to your system. GPSL does not guarantee that the integrity of this
communication has been maintained nor that this communication is free of
viruses, interceptions or interference and makes no warranties in relation to
these matters. This is not an offer or a solicitation to buy or sell
securities or investment products, or an official confirmation. GPSL record
electronic and phone communications in accordance with FCA and MiFID2
regulations, they will be monitored for regulatory and training purposes. GPSL
[5] is authorised and regulated by the Financial Conduct Authority of the
United Kingdom (Firm Reference Number: 225563).
Click on the following link for the GPSL MiFID2 Investor Guidance Notice [6]
Recommendation Overview (MAR) [7]
GPSL Equity Research publications are available on the following aggregators
and via news distribution circuits (For Institutional Use Only): AlphaMetry
[8], AlphaSense, Bloomberg (GOET), Capital IQ, EQS, FACTSET, ResearchFN [9],
Research Tree [10], RNS Reach, Sentieo [11] and Thomson Reuters.
Please copy the below link and paste it into your browser for the full pdf
version of the equity research report:
https://gp.bluematrix.com/sellside/EmailDocViewer?encrypt=a1586179-81e3-43cf-8
c08-5165ff215d7b&mime=pdf&co=gp&id=paul.dunne@goetzpartners.com&source=library
View [12]
*Free to access research and investor meetings in a post-MiFID2 world.*
*This research report is intended for use only by persons who qualify as
professional investors or eligible counterparties (institutional investors) in
the applicable jurisdiction, and not by any private individuals or other
persons who qualify as retail clients.*
Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
End of Announcement - EQS News Service
788831 18-March-2019
1: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=750ca54579c5d5447638f7f35718f4d1&application_id=788831&site_id=vwd&application_name=news
2: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=4e235136b3fff70f6e9b300faf1356df&application_id=788831&site_id=vwd&application_name=news
(MORE TO FOLLOW) Dow Jones Newswires
March 18, 2019 16:05 ET (20:05 GMT)
3: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=e4cf3d45df1d07e4e36e54790266d6f1&application_id=788831&site_id=vwd&application_name=news 4: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=105c239b1a4ab584252dd4cb0ab60fcc&application_id=788831&site_id=vwd&application_name=news 5: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=ba4d174d6cc17a15461e9920a97cb6e6&application_id=788831&site_id=vwd&application_name=news 6: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=3a7dca011f706488817dc0ced9cb1594&application_id=788831&site_id=vwd&application_name=news 7: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=1261a15aa8b95d39f3ac2a94fe23414a&application_id=788831&site_id=vwd&application_name=news 8: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=74ec96f086effd6902b227645be3904c&application_id=788831&site_id=vwd&application_name=news 9: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=4ca72a1f25bfe4e057f55b4178d31406&application_id=788831&site_id=vwd&application_name=news 10: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=e6502ecec4e43c9ec21d32670b12b227&application_id=788831&site_id=vwd&application_name=news 11: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=e3895772493fb088c9401b3187f667a7&application_id=788831&site_id=vwd&application_name=news 12: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=3f7bb6c04eba4109085947c24f48060d&application_id=788831&site_id=vwd&application_name=news
(END) Dow Jones Newswires
March 18, 2019 16:05 ET (20:05 GMT)
© 2019 Dow Jones News
